FDA agrees to review Takeda and Affymax's anemia drug

07/27/2011 | Xconomy

Affymax and Takeda Pharmaceutical's drug candidate peginesitide was accepted for FDA review. Formerly named Hematide, the once-monthly drug is intended for anemia in kidney patients on dialysis.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel
Regeneron
Tarrytown, NY
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Senior Counsel – Healthcare Regulatory #29099BR
Amgen
Thousand Oaks, CA
R&D Engineer
Access Scientific
San Diego, CA, CA